tbuckley/cabot-search huggingface dataset:
Abstract 13820: Temporal Trends and Prognosis of Physical Exam Findings in Patients Hospitalized With Acute Decompensated Heart Failure With Preserved versus Reduced Ejection Fraction the Aric Study Community Surveillance
Authors: Abhigna Kolupoti, Ambarish Pandey, Anna Kucharska-newton, Michael E Hall, Muthiah Vaduganathan, Robert J Mentz, Melissa Caughey
Journal: Circulation (2020)

Introduction: Bedside evaluation of congestion remains important in both heart failure (HF) with reduced and preserved ejection fraction (HFrEF and HFpEF). Whether presence of physical exam findings have changed over time, or if prognosis of physical examination differs by HF type is uncertain. Methods: From 2005-2014, the Atherosclerosis Risk in Communities (ARIC) Study conducted hospital surveillance of acute decompensated heart failure (ADHF). Events were verified by physician review, and clinical data were abstracted from the medical record. We examined presence of 3 physical exam findings suggesting congestion: lower extremity edema, jugular venous distension, and pulmonary rales &gt; 1/3 of the lung field. Analyses were weighted by sampling fractions. Results: Of 24,937 hospitalizations for ADHF (mean age 75 years, 53% women, 32% black), 47% were HFpEF. Presence of edema increased from 2005-2009 to 2010-2014, both for HFpEF (66% to 72%; P for annual trend = 0.002) and HFrEF (62% to 67%; P for annual trend = 0.009), while presence of rales and jugular distention remained stable. There were 2640 (11%) and 7766 (31%) deaths within 28 days and 1 year of hospitalization, respectively. Patients with HFpEF and all 3 physical exam signs had a greater risk of short- and long-term mortality ( Figure ). After adjustments for demographics and length of stay, there was a differential association between clinical signs and 28-day mortality by HF type ( P for interaction = 0.02). Presence of all 3 vs. &lt;3 signs was associated with increased mortality for HFpEF (HR = 2.22; 95% CI: 1.51 - 3.27) but not HFrEF (HR = 1.13; 95% CI: 0.79 - 1.61). A similar association was observed for 1-year mortality (HFpEF: HR = 1.49; 95% CI: 1.13 - 1.98) vs. (HFrEF: HR = 1.13; 95% CI: 0.91 - 1.40). Conclusion: The presence of edema on physical examination of patients with ADHF has increased in recent years, both for HFpEF and HFrEF. However, the prognostic utility of physical exam signs of congestion may differ by HF type.
Abstract 17292: Does Morbid Obesity Worsens Outcomes in COVID-19?
Authors: Sohaib Roomi, Waqas Ullah, Nayab Nadeem, Rehan Saeed, Donald Haas, Margot Boigon
Journal: Circulation (2020)

Introduction: Given the high prevalence of obesity around the globe, patients with coronavirus disease 2019 (COVID-19) are at an increased risk of devastating complications. Hypothesis: We hypothesize that morbid obesity is independently associated with increased risk of in-hospital mortality, upgrade to intensive care unit, invasive mechanical ventilation(IVM), and acute renal failure necessitating dialysis. Methods: A retrospective cohort study was performed to determine the association of basal metabolic index (BMI) with the above-mentioned outcomes. Independent t-test and multivariate logistic regression analysis were performed to calculate mean differences and adjusted odds ratios (aOR) with its 95% confidence interval (CI), respectively. Results: A total of 176 patients with confirmed COVID-19 diagnosis were included. The mean age was 62.2 years, with 51% of male patients. The mean BMI for non-surviving patients was significantly higher compared to patients surviving on the 7th day of hospitalization (35 vs. 30 kg/m2, p=0.022) and patients with a higher BMI had higher in-hospital mortality (21% vs. 9%, OR 3.2, 95% CI 1.3-8.2, p=0.01) compared to patients with a normal BMI. Similarly, patients requiring IMV had a higher BMI (33 vs. 29, p=0.002) compared to non-intubated patients. aOR of patients needing IMV (56% vs. 28%, OR 3.3, 95% CI 1.6-7.0, p=0.002) and upgrade to ICU (46% vs. 28%, OR 2.2, 1.07-4.6, p=0.04) were significantly higher compared to patients with a lower BMI. There was no significant difference between the two groups in terms of the need for dialysis (5% vs. 13%, OR 3.8, 13% vs. 4%, 1.1-14.1, p=0.07). Adjusted odds ratios controlled for baseline comorbidities and medications mirrored the overall results, except for the need to upgrade to ICU. Conclusions: In patients with confirmed COVID-19, morbid obesity serves as an independent risk factor of high in-hospital mortality and the need for invasive mechanical ventilation.
Abstract 16667: Computed Tomography-Based Pulmonary Vascular Tortuosity as a Marker in Resting and Exercise Pulmonary Arterial Hypertension
Authors: Eileen M Harder, Pietro Nardelli, Gonzalo Sanchez-Ferrero, James Ross, Sam Y Ash, Inderjit Singh, Andetta Hunsaker, Aaron B Waxman, Raul San Jose Estepar, George Washko, Farbod Rahaghi
Journal: Circulation (2020)

Introduction: Increased vascular tortuosity has been proposed as a marker of pulmonary arterial hypertension (PAH). In this analysis, we compared arterial and venous vascular tortuosity between controls and subjects with resting PAH. Furthermore, we examined if abnormalities could be detected in exercise PAH (EPAH), thought to be an early form of PAH. Methods: From an institutional registry, 388 patients with both right heart catheterization and computed tomography angiography (CTA) data were selected. Within this cohort, three distinct groups were identified: 1) controls, who had no cardiopulmonary disease and normal resting and exercise hemodynamics; 2) EPAH, with normal resting hemodynamics but age-adjusted pre-capillary pulmonary hypertension on exertion, and 3) PAH, defined as resting mPAP &gt;20mmHg, pulmonary vascular resistance &gt;3 Wood Units, and pulmonary capillary wedge pressure &lt;15mmHg. Tortuosity was defined as the actual path length of a vessel divided by the linear distance between the two farthest endpoints of the vessel segment on CTA. AV&gt;10% was defined as the number of arterial segments with tortuosity &gt;10% divided by the same venous measure. Analysis was performed with Wilcoxon rank sum tests in R 3.5. Results: There were 99 patients in the final cohort, including 47 (47.4%) with PAH, 12 (12.1%) with EPAH, and 40 (40.4%) without disease. Compared to controls, median arterial tortuosity was increased in PAH (3.3 ± 0.1% vs. 3.4 ± 0.1%, p=0.0009; Figure 1) but not in EPAH (3.3 ± 0.1%, p=0.82). Median venous tortuosity did not differ between groups. AV&gt;10% was increased in EPAH (vs. controls, 1.86 ± 0.38 vs. 1.56 ± 0.44, p=0.03) and resting PAH (2.0 ± 1.2 p=2e-6). Conclusions: Increased arterial tortuosity on CTA is a biomarker of resting PAH. When corrected for venous tortuosity, arterial tortuosity also appears to be abnormal in EPAH. Figure 1 . Arterial vessels in PAH, EPAH, and control subjects. Red segments have tortuosity &gt; 10%.
Gut microbiota–specific IgA <sup>+</sup> B cells traffic to the CNS in active multiple sclerosis
Authors: Anne-Katrin Pröbstel, Xiaoyuan Zhou, Ryan Baumann, Sven Wischnewski, Michael Kutza, Olga L. Rojas, Katrin Sellrie, Antje Bischof, Kicheol Kim, Akshaya Ramesh, Ravi Dandekar, Ariele L. Greenfield, Ryan D. Schubert, Jordan E. Bisanz, Stephanie Vistnes, Khashayar Khaleghi, James Landefeld, Gina Kirkish, Friederike Liesche-Starnecker, Valeria Ramaglia, Sneha Singh, Edwina B. Tran, Patrick Barba, Kelsey Zorn, Johanna Oechtering, Karin Forsberg, Lawrence R. Shiow, Roland G. Henry, Jennifer Graves, Bruce A. C. Cree, Stephen L. Hauser, Jens Kuhle, Jeffrey M. Gelfand, Peter M. Andersen, Jürgen Schlegel, Peter J. Turnbaugh, Peter H. Seeberger, Jennifer L. Gommerman, Michael R. Wilson, Lucas Schirmer, Sergio E. Baranzini
Journal: Science Immunology (2020)

Changes in gut microbiota composition and a diverse role of B cells have recently been implicated in multiple sclerosis (MS), a central nervous system (CNS) autoimmune disease. Immunoglobulin A (IgA) is a key regulator at the mucosal interface. However, whether gut microbiota shape IgA responses and what role IgA+ cells have in neuroinflammation are unknown. Here, we identify IgA-bound taxa in MS and show that IgA-producing cells specific for MS-associated taxa traffic to the inflamed CNS, resulting in a strong, compartmentalized IgA enrichment in active MS and other neuroinflammatory diseases. Unlike previously characterized polyreactive anti-commensal IgA responses, CNS IgA cross-reacts with surface structures on specific bacterial strains but not with brain tissue. These findings establish gut microbiota-specific IgA+ cells as a systemic mediator in MS and suggest a critical role of mucosal B cells during active neuroinflammation with broad implications for IgA as an informative biomarker and IgA-producing cells as an immune subset to harness for therapeutic interventions.
Regulation of Over-the-Counter Hearing Aids — Deafening Silence from the FDA
Authors: Kevin H. Franck, Vinay K. Rathi
Journal: New England Journal of Medicine (2020)

In August 2020, the FDA missed a statutory deadline to release rules governing over-the-counter hearing aids. It's unclear when the agency will fulfill its legal obligation to establish regulations that are expected to increase treatment access for millions of people.
Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors
Authors: Mark K. Bakker, Rick A. A. van der Spek, Wouter van Rheenen, Sandrine Morel, Romain Bourcier, Isabel C. Hostettler, Varinder S. Alg, Kristel R. van Eijk, Masaru Koido, Masato Akiyama, Chikashi Terao, Koichi Matsuda, Robin G. Walters, Kuang Lin, Liming Li, Iona Y. Millwood, Zhengming Chen, Guy A. Rouleau, Sirui Zhou, Kristiina Rannikmäe, Cathie L. M. Sudlow, Henry Houlden, Leonard H. van den Berg, Christian Dina, Olivier Naggara, Jean-Christophe Gentric, Eimad Shotar, François Eugène, Hubert Desal, Bendik S. Winsvold, Sigrid Børte, Marianne Bakke Johnsen, Ben M. Brumpton, Marie Søfteland Sandvei, Cristen J. Willer, Kristian Hveem, John-Anker Zwart, W. M. Monique Verschuren, Christoph M. Friedrich, Sven Hirsch, Sabine Schilling, Jérôme Dauvillier, Olivier Martin, Gregory T. Jones, Matthew J. Bown, Nerissa U. Ko, Helen Kim, Jonathan R. I. Coleman, Gerome Breen, Jonathan G. Zaroff, Catharina J. M. Klijn, Rainer Malik, Martin Dichgans, Muralidharan Sargurupremraj, Turgut Tatlisumak, Philippe Amouyel, Stéphanie Debette, Gabriel J. E. Rinkel, Bradford B. Worrall, Joanna Pera, Agnieszka Slowik, Emília I. Gaál-Paavola, Mika Niemelä, Juha E. Jääskeläinen, Mikael von Und Zu Fraunberg, Antti Lindgren, Joseph P. Broderick, David J. Werring, Daniel Woo, Richard Redon, Philippe Bijlenga, Yoichiro Kamatani, Jan H. Veldink, Ynte M. Ruigrok
Journal: Nature Genetics (2020)
Abstract 13711: Coronary Artery Calcium, Ankle-brachial Index, High Sensitivity C-reactive Protein, and a Family History of Coronary Artery Disease as Predictors of Incident Cardiovascular Events at Different Stages of Hypertension: The Multi-ethnic Study of Atherosclerosis
Authors: Radha Kanneganti, Zeina Dardari, Roger S Blumenthal, Ron Blankstein, Arthur S Agatston, Matthew J Budoff, Karol E Watson, Gregory Burke, Erin D Michos, Khurram Nasir, Michael J Blaha, Rajesh Tota-Maharaj
Journal: Circulation (2020)

Background: Coronary artery calcium (CAC), ankle-brachial index (ABI), high-sensitivity CRP (hsCRP), and family history (FHx) of coronary artery disease (CAD) are used as complementary aids in cardiac risk stratification. The 2017 ACC/AHA hypertension guideline’s new Stage I hypertension group has created uncertainty regarding intensity of blood pressure (BP) treatment in this group. We evaluated the comparative utility of CAC, ABI, hsCRP and FHx CAD as risk predictors of cardiovascular (CVD) events within different BP strata. Methods: The MESA cohort was followed for a median of 13 years with regards to incident coronary heart disease (CHD) and CVD events. BP was categorized per ACC/AHA guideline: normal- &lt;120/&lt;80, elevated 120-129/&lt;80, stage I 130-139/80-89, and stage II ≥140/≥90. Participants on BP medications were assigned stage II. Cox regression was used to compare prediction of CHD and CVD events by CAC&gt;300, CAC&gt;75 t h %, ABI&lt;0.9, hsCRP&gt;2 mg/L and FHx CAD, stratifying by BP groups after adjusting for demographics, CVD risk factors and use of BP and cholesterol medications. Results: Of 6268 persons, 539 incident CHD events and 572 incident CVD events were noted. CAC&gt;300 and CAC&gt;75 th % predicted an increased CHD event risk throughout all BP groups. ABI&lt;0.9 was predictive of CHD events in stage I and II, while hsCRP was not predictive in any group. CAC&gt;300 predicted a 2-fold increased CVD risk in all BP groups after adjustment. In the Stage I group, CAC&gt;300, CAC&gt;75 th % and ABI&lt;0.9 showed additive predictive value in incident CHD and CVD events. Using the adjusted model to predict CHD survival, CAC&gt;300 had a consistently higher C-statistic throughout all BP categories compared to other risk markers. Conclusion: CAC&gt;300 was associated with increased CHD and CVD risk in all BP groups and demonstrated superior prognostic utility compared to other risk markers. CAC&gt;300, CAC&gt;75 th % and ABI&lt;0.9 showed potential as risk modifiers in the new Stage I hypertension group.
Abstract 13330: Intrarenal Doppler Ultrasonography Reflects Hemodynamics and Predicts Prognosis in Patients With Heart Failure
Authors: Koichiro Watanabe, Akiomi YOSHIHISA, Yu Sato, Yu Hotsuki, Yasuhiro Ichijo, Yusuke KIMISHIMA, Tetsuro Yokokawa, Tomofumi Misaka, Masayoshi Oikawa, ATSUSHI KOBAYASHI, Yasuchika Takeishi
Journal: Circulation (2020)

Introduction: We aimed to clarify clinical implications of intrarenal hemodynamics (congestion and hypoperfusion) assessed by intrarenal Doppler ultrasonography (IRD) and their prognostic impacts in patients with heart failure (HF). Methods and Results: We performed IRD and measured interlobar renal artery velocity time integral (VTI) and intrarenal venous flow (IRVF) patterns (monophasic or non-monophasic pattern) to assess intrarenal hypoperfusion and congestion in HF patients (n=341). These patients were categorized based on 1) VTI: high VTI (VTI ≥ 14.0 cm, n=231) or low VTI (VTI &lt; 14.0 cm, n=103); and 2) IRVF: monophasic (n=36) or non-monophasic (n=305) pattern. We performed right-heart catheterization, and examined post-discharge cardiac event rate such as cardiac death and rehospitalization due to worsening HF. Regarding renal perfusion, cardiac index was positively correlated with VTI (R=0.270, P=0.040). Concerning renal congestion, levels of right atrial pressure were higher in monophasic pattern than in non-monophasic pattern (9.0 vs. 7.2 mmHg, P=0.029). Importantly, HF patients with low VTI and a monophasic IRVF pattern (subset 4) had the highest cardiac event rate ( Figure ). In the Cox proportional hazard analysis, the combination of low VTI and a monophasic IRVF pattern was found to be a strong predictor of cardiac events (HR 8.357, 95% CI 3.365-20.752). Conclusion: Intrarenal hypoperfusion and congestion assessed by IRD imaging reflected cardiac output and right atrial pressure, and was useful to risk-stratify HF patients.
A Middle-aged Woman With Severe Scoliosis and Encephalopathy
Authors: Gomathi Mohan, Geetha Bharathi, Balachandar Vellingiri
Journal: JAMA Neurology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 14986: A Randomized Trial of Statins to Reduce Vascular Endothelial Inflammation in Psoriasis
Authors: Michael S Garshick, Florencia Schlamp, Tessa Barrett, Michael Tawil, Jose Scher, Andrea Neimann, Sanja Jelic, Stuart D Katz, Sandra Garcet, Fisher Edward, James Krueger, Jeffrey S Berger
Journal: Circulation (2020)

Introduction: Psoriasis (PsO) is a chronic skin disease associated with increased CV risk. Systemic and vascular endothelial inflammation in PsO is highly prevalent and associated with CVD. Statins reduce LDL-C, systemic inflammation, and CV events. There is minimal data supporting the use of statins in PsO. We, therefore, investigated the effect of statins on circulating and vascular endothelial biomarkers of CV risk in PsO. Methods: We performed blood RNA sequencing, targeted proteomics (n=88), and brachial vein endothelial harvesting in PsO participants (n=45, average age 45 ± 14 years, 49% male, body surface area [BSA] of PsO 8 ± 14%, Framingham Risk Score 6 ± 7%) and age- gender-matched controls (n=18). Next, PsO subjects were randomly assigned to 40 mg atorvastatin (n=15) or no-treatment (n=10). A repeat assessment occurred at week two with the primary end-point change in vascular endothelial inflammation (mean composite of LTB, CCL3, CX3CL1, CCL2, CXCL1, ICAM1, iNOS, IL-8, IL-1B, COX- 2 expression). Results: Blood RNA sequencing with pathway analysis revealed inflammasome signaling as highly upregulated in PsO compared to control with protein expression of IL-6 ( r =0.68, p &lt;0.001) and hs-CRP ( r =0.80, p &lt;0.001) each correlated with PsO severity (psoriasis area and severity index [PASI]). Mean vascular endothelial inflammation was also 3-fold higher ( p =0.02) in PsO compared to control and correlated with both PASI ( r =0.40, p =0.01) and LDL-C ( r =0.29, p =0.05). In PsO patients randomized to two weeks of statin therapy, LDL-C was reduced by ~50% compared to the no-treatment group (60 mg/dL vs. 111 mg/dL, p &lt;0.001 respectively). While no decrease in inflammatory pathways at the whole blood transcriptome and protein levels were noted, vascular endothelial inflammation was 60% lower in the statin vs. no-treatment group ( p =0.02). Change in vascular endothelial inflammation correlated with change in LDL-C ( r =0.53, p &lt;0.05) but not IL-6 ( r =-0.25, p =0.30) or hs-CRP ( r =0.15, p =0.58). Conclusions: Two-weeks of high-intensity atorvastatin reduced vascular endothelial but not systemic inflammation in PsO. These findings suggest that statins may reduce CV risk in PsO either through lipid-mediated or a direct effect of statins on the vascular endothelium.
A DNA methylation state transition model reveals the programmed epigenetic heterogeneity in human pre-implantation embryos
Authors: Chengchen Zhao, Naiqian Zhang, Yalin Zhang, Nuermaimaiti Tuersunjiang, Shaorong Gao, Wenqiang Liu, Yong Zhang
Journal: Genome biology (2020)

Abstract Background During mammalian early embryogenesis, expression and epigenetic heterogeneity emerge before the first cell fate determination, but the programs causing such determinate heterogeneity are largely unexplored. Results Here, we present MethylTransition, a novel DNA methylation state transition model, for characterizing methylation changes during one or a few cell cycles at single-cell resolution. MethylTransition involves the creation of a transition matrix comprising three parameters that represent the probabilities of DNA methylation-modifying activities in order to link the methylation states before and after a cell cycle. We apply MethylTransition to single-cell DNA methylome data from human pre-implantation embryogenesis and elucidate that the DNA methylation heterogeneity that emerges at promoters during this process is largely an intrinsic output of a program with unique probabilities of DNA methylation-modifying activities. Moreover, we experimentally validate the effect of the initial DNA methylation on expression heterogeneity in pre-implantation mouse embryos. Conclusions Our study reveals the programmed DNA methylation heterogeneity during human pre-implantation embryogenesis through a novel mathematical model and provides valuable clues for identifying the driving factors of the first cell fate determination during this process.
Abstract 16631: Predictors of Left Ventricular Dysfunction in Patients After Anatomic Repair of Congenitally Corrected Transposition of the Great Arteries
Authors: Megan Wilde, Andrew Rodenbarger, Rebecca Hartog, Tiffany Lim, Kimberly Watkins, Ray Lowery, Sunkyung Yu, Katherine Afton, Caren S Goldberg, Jimmy C Lu, Richard G Ohye, Adam L Dorfman
Journal: Circulation (2020)

Introduction: After anatomic repair (AR) of congenitally corrected transposition of the great arteries (ccTGA), the left ventricle (LV) is re-established as the systemic ventricle. As such, LV dysfunction is an important factor in long-term patient morbidity. While predictors exist for successful AR, little is known regarding measures of LV function before and after AR, and no known predictors exist of worsening global longitudinal strain (GLS). Methods: All patients with ccTGA who survived to discharge after AR at a single institution from 2000-2018 were included. Pre-operative and discharge echocardiograms were reviewed and GLS analysis was performed. LV sphericity index was measured to determine the degree of ventricular septal shift; a lower index denotes more septal bowing into the LV. Logistic regression was used to identify factors associated with worsened GLS after AR. Results: Of 91 survivors (65% male), 51 underwent Senning/arterial switch (ASO) and 40 had Senning/Rastelli. Mean LV ejection fraction (EF) decreased from 66% to 61% after AR (p = 0.0003) with 26% having LVEF less than or equal to 55% (increased from 4% pre-op, p = 0.0003). Mean LV GLS was normal pre-op (-20.0% ± SD 4.1%) but worsened following AR (-16.5% ± 4.6%; p &lt;.0001); abnormal LV GLS (&gt; -18%) increased to 62% (vs 32% pre-op, p &lt;.0001). More patients undergoing Senning/ASO (78%) had abnormal LV GLS at discharge compared to those with a Senning/Rastelli (22%) (odds ratio [OR] 9.3, p &lt;.0001). Abnormal pre-op GLS (OR 5.8, p = 0.002) and lower LV sphericity index (OR 1.05, p = 0.01) were also significantly associated with worsening GLS at discharge. In multivariable analysis, all three remained independently associated with worsened LV GLS. Age at AR, ventricular looping, LV posterior wall thickness, and reintervention prior to discharge were not associated with changed LV GLS at discharge. Conclusions: Following AR of ccTGA, LVEF decreases but remains in the normal range, while LV GLS detects abnormalities. Risk factors for worsening GLS include abnormal pre-op LV GLS, lower LV sphericity index, and a Senning/ASO repair. Lower LV sphericity index, or more septal shift into the LV, may represent a “less trained” LV, highlighting the need for careful patient selection for AR.
Cause of Death in Patients With Acute Heart Failure
Authors: Rahul S. Loungani, John R. Teerlink, Marco Metra, Larry A. Allen, Javed Butler, Peter E. Carson, Chien-Wei Chen, Gad Cotter, Beth A. Davison, Zubin J. Eapen, Gerasimos S. Filippatos, Claudio Gimpelewicz, Barry Greenberg, Thomas Holbro, James L. Januzzi, David E. Lanfear, Peter S. Pang, Ileana L. Piña, Piotr Ponikowski, Alan B. Miller, Adriaan A. Voors, G. Michael Felker
Journal: JACC Heart Failure (2020)